Volume 80, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


The treatment for hydrocele is expensive, invasive surgery—hydrocelectomy. A drug that could prevent or improve this condition could replace or supplement hydrocelectomy. In Ghana, 42 hydrocele patients participated in a double-blind, placebo-controlled trial of a six-week regimen of doxycycline, 200 mg/day. Four months after doxycycline treatment, patients received 150 μg/kg of ivermectin and 400 mg of albendazole, which is used for mass chemotherapy in this area. Patients were monitored for levels of sp., microfilaremia, antigenemia, plasma levels of vascular endothelial growth factor-A (VEGF-A) and stage/size of the hydrocele. sp. loads/microfilaria, microfilaremia, and antigenemia were significantly reduced in the doxycycline-treated patients compared with the placebo group. The mean plasma levels of VEGF-A were decreased significantly in the doxycycline-treated patients who had active infection. This finding preceded the reduction of the stage of hydrocele. A six-week regimen of doxycycline treatment against filariasis showed amelioration of pathologic conditions of hydrocele patients with active infection.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Ottesen EA, 2000. The global programme to eliminate lymphatic filariasis. Trop Med Int Health 5 : 591–594. [Google Scholar]
  2. Addiss DG, Brady MA, 2007. Morbidity management in the global programme to eliminate lymphatic filariasis: a review of the scientific literature. Filaria J 6 : 2. [Google Scholar]
  3. World Health Organization, 2006. Global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec 81 : 221–232. [Google Scholar]
  4. Eigege A, Richards FO Jr, Blaney DD, Miri ES, Gontor I, Ogah G, Umaru J, Jinadu MY, Mathai W, Amadiegwu S, Hopkins DR, 2003. Rapid assessment for lymphatic filariasis in central Nigeria: a comparison of the immunochromatographic card test and hydrocele rates in an area of high endemicity. Am J Trop Med Hyg 68 : 643–646. [Google Scholar]
  5. Jordan P, 1957. The fevers of Africa. 5. Clinical bancroftian disease in Tankanyika. Cent Afr J Med 3 : 18–23. [Google Scholar]
  6. Dreyer G, Nores J, Addis D, 1997. The silent burden of sexual disability associated with lymphatic filariasis. Acta Trop 63 : 57–60. [Google Scholar]
  7. Wegesa P, McMahon JE, Abaru DE, Hamilton PJ, Marshall TF, Vaughan JP, 1979. Tanzania filariasis project: survey methodology and clinical manifestations of bancroftian filariasis. Acta Trop 36 : 369–377. [Google Scholar]
  8. Mwobobia IK, Muniu EM, Kombe Y, Wamae CN, 2000. Hydrocelectomy: a proxy for hydrocele prevalence in coastal Kenya. Ann Trop Med Parasitol 94 : 479–484. [Google Scholar]
  9. DeVries CR, 2002. The role of the urologist in the treatment and elimination of lymphatic filariasis worldwide. BJU Int 89 (Suppl 1): 37–43. [Google Scholar]
  10. Ottesen EA, 1992. The Wellcome Trust Lecture. Infection and disease in lymphatic filariasis: an immunological perspective. Parasitology 104 (Suppl): S71–S79. [Google Scholar]
  11. Ottesen EA, 1980. Immunopathology of lymphatic filariasis in man. Springer Semin Immunopathol 2 : 373–385. [Google Scholar]
  12. Ottesen EA, Weller PF, Lunde MN, Hussain R, 1982. Endemic filariasis on a Pacific Island. II. Immunologic aspects: immunoglobulin, complement, and specific antifilarial IgG, IgM, and IgE antibodies. Am J Trop Med Hyg 31 : 953–961. [Google Scholar]
  13. Debrah AY, Mand S, Toliat RM, Marfo-Debrekyei Y, Batsa L, Nuernberg P, Lawson B, Adjei O, Hoerauf A, Pfarr K, 2007. Plasma vascular endothelial growth factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis. Am J Trop Med Hyg 77 : 601–608. [Google Scholar]
  14. Ferrara N, 2000. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55 : 15–35. [Google Scholar]
  15. Carmeliet P, 2000. VEGF gene therapy: stimulating angiogenesis or angiomagenesis? Nat Med 6 : 1102–1103. [Google Scholar]
  16. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S, 2002. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51 : 1635–1639. [Google Scholar]
  17. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P, 2004. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 53 : 861–864. [Google Scholar]
  18. Dvorak HF, Brown LF, Detmar M, Dvorak AM, 1995. Vascular permeability factor/vascular endothelial growth factor, micro-vascular hyperpermeability, and angiogenesis. Am J Pathol 146 : 1029–1039. [Google Scholar]
  19. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF, 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 : 983–985. [Google Scholar]
  20. Esterre P, Plichart C, Huin-Blondey MO, Nguyen LN, 2005. Soluble cellular adhesion molecules, selectins, VEGF and endothelin-1 in patients with Wuchereria bancrofti infection and association with clinical status. Parasite Immunol 27 : 9–16. [Google Scholar]
  21. Debrah AY, Mand S, Specht S, Marfo-Debrekyei Y, Batsa L, Pfarr K, Larbi J, Lawson B, Taylor M, Adjei O, Hoerauf A, 2006. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog 2 : e92. [Google Scholar]
  22. Turner JD, Mand S, Debrah AY, Muehlfeld J, Pfarr K, McGarry HF, Adjei O, Taylor MJ, Hoerauf A, 2006. A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection. Clin Infect Dis 42 : 1081–1089. [Google Scholar]
  23. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K, 1998. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem 273 : 8413–8418. [Google Scholar]
  24. Rutkowski JM, Moya M, Johannes J, Goldman J, Swartz MA, 2006. Secondary lymphedema in the mouse tail: lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9. Microvasc Res 72 : 161–171. [Google Scholar]
  25. Gyapong M, Gyapong J, Weiss M, Tanner M, 2000. The burden of hydrocele on men in northern Ghana. Acta Trop 77 : 287–294. [Google Scholar]
  26. Meyrowitsch DW, Simonsen PE, Makunde WH, 1996. Mass DEC chemotherapy for control of bancroftian filariasis: comparative efficacy of four strategies two years after start of treatment. Trans R Soc Trop Med Hyg 90 : 423–428. [Google Scholar]
  27. Bockarie MJ, Alexander ND, Hyun P, Dimber Z, Bockarie F, Ibam E, Alpers MP, Kazura JW, 1998. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes. Lancet 351 : 162–168. [Google Scholar]
  28. Bockarie MJ, Tisch DJ, Kastens W, Alexander ND, Dimber Z, Bockarie F, Ibam E, Alpers MP, Kazura JW, 2002. Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med 347 : 1841–1848. [Google Scholar]
  29. Bernhard P, Magnussen P, Lemnge MM, 2001. A randomized, double-blind, placebo-controlled study with diethylcarbamazine for the treatment of hydrocoele in an area of Tanzania endemic for lymphatic filariasis. Trans R Soc Trop Med Hyg 95 : 534–536. [Google Scholar]
  30. Kyelem D, Sanou S, Boatin B, Medlock J, Coulibaly S, Molyneux DH, 2003. Impact of long-term ivermectin (Mectizan) on Wuchereria bancrofti and Mansonella perstans infections in Burkina Faso: strategic and policy implications. Ann Trop Med Parasitol 97 : 827–838. [Google Scholar]
  31. Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, Debrah AY, Pfarr KM, Adjei O, Buttner DW, 2003. Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol (Berl) 192 : 211–216. [Google Scholar]
  32. Mand S, Marfo-Debrekyei Y, Dittrich M, Fischer K, Adjei O, Hoerauf A, 2003. Animated documentation of the filaria dance sign (FDS) in bancroftian filariasis. Filaria J 2 : 3. [Google Scholar]
  33. Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A, 2005. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 365 : 2116–2121. [Google Scholar]
  34. World Health Organization, 1997. Chagas disease, leprosy, lymphatic filariasis, onchocerciasis: prospects for elimination. TDR/ Gen 97: 17–22. [Google Scholar]
  35. Michael E, Bundy DA, Grenfell BT, 1996. Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitol 112 : 409–428. [Google Scholar]
  36. Ottesen EA, Duke BO, Karam M, Behbehani K, 1997. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 75 : 491–503. [Google Scholar]
  37. Addiss DG, Brady MA, 2007. Morbidity management in the global programme to eliminate lymphatic filariasis: a review of the scientific literature. Filaria J 6 : 2. [Google Scholar]
  38. Faris R, Hussain O, El Setouhy M, Ramzy RM, Weil GJ, 1998. Bancroftian filariasis in Egypt: visualization of adult worms and subclinical lymphatic pathology by scrotal ultrasound. Am J Trop Med Hyg 59 : 864–867. [Google Scholar]
  39. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K, 1997. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276 : 1423–1425. [Google Scholar]
  40. Peixoto CA, Figueiredo-Silva J, 2001. Fine structure of intrascrotal lymphatic vessels infected by Wuchereria bancrofti adult worms. J Submicrosc Cytol Pathol 33 : 125–131. [Google Scholar]
  41. Norões J, Addiss D, Santos A, Medeiros Z, Coutinho A, Dreyer G, 1996. Ultrasonographic evidence of abnormal lymphatic vessels in young men with adult Wuchereria bancrofti infection in the scrotal area. J Urol 156 : 409–412. [Google Scholar]
  42. Saaristo A, Tammela T, Timonen J, Yla-Herttuala S, Tukiainen E, Asko-Seljavaara S, Alitalo K, 2004. Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB J 18 : 1707–1709. [Google Scholar]
  43. Yoon YS, Murayama T, Gravereaux E, Tkebuchava T, Silver M, Curry C, Wecker A, Kirchmair R, Hu CS, Kearney M, Ashare A, Jackson DG, Kubo H, Isner JM, Losordo DW, 2003. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest 111 : 717–725. [Google Scholar]
  44. Karkkainen MJ, Jussila L, Ferrell RE, Finegold DN, Alitalo K, 2001. Molecular regulation of lymphangiogenesis and targets for tissue oedema. Trends Mol Med 7 : 18–22. [Google Scholar]
  45. Ottesen E, Weil GJ, 2004. Towards a strategic plan for research to support the global programme to eliminate lymphatic filariasis. Am J Trop Med Hyg 71 (Suppl): 1–2. [Google Scholar]

Data & Media loading...

  • Received : 04 Dec 2007
  • Accepted : 26 Feb 2009

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error